 Jennifer Schuster
Concepts (348)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 15 | 2024 | 57 | 4.370 |
Why?
| | Respiratory Tract Infections | 15 | 2023 | 75 | 4.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2024 | 50 | 3.830 |
Why?
| | Influenza Vaccines | 11 | 2024 | 24 | 3.710 |
Why?
| | Humans | 104 | 2024 | 6599 | 3.640 |
Why?
| | Enterovirus Infections | 12 | 2023 | 37 | 3.450 |
Why?
| | Enterovirus D, Human | 11 | 2023 | 25 | 3.220 |
Why?
| | Child | 72 | 2024 | 3146 | 3.220 |
Why?
| | Child, Preschool | 36 | 2024 | 1459 | 2.380 |
Why?
| | Hospitalization | 29 | 2024 | 192 | 2.380 |
Why?
| | United States | 34 | 2024 | 646 | 2.290 |
Why?
| | Metapneumovirus | 9 | 2022 | 12 | 2.280 |
Why?
| | Paramyxoviridae Infections | 8 | 2016 | 12 | 2.200 |
Why?
| | Schools | 8 | 2023 | 49 | 2.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2024 | 12 | 2.040 |
Why?
| | Adolescent | 42 | 2024 | 2087 | 1.900 |
Why?
| | Disease Outbreaks | 11 | 2023 | 30 | 1.850 |
Why?
| | Antibodies, Viral | 8 | 2024 | 46 | 1.790 |
Why?
| | Rhinovirus | 5 | 2023 | 11 | 1.590 |
Why?
| | Infant | 30 | 2024 | 1396 | 1.520 |
Why?
| | Female | 35 | 2024 | 3436 | 1.430 |
Why?
| | Virus Diseases | 2 | 2020 | 11 | 1.380 |
Why?
| | Vaccination | 16 | 2024 | 68 | 1.360 |
Why?
| | Male | 34 | 2023 | 3197 | 1.350 |
Why?
| | Systemic Inflammatory Response Syndrome | 10 | 2023 | 16 | 1.280 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 5 | 2021 | 9 | 1.260 |
Why?
| | Pandemics | 11 | 2024 | 78 | 1.170 |
Why?
| | Prospective Studies | 18 | 2024 | 508 | 1.140 |
Why?
| | Vulnerable Populations | 2 | 2023 | 7 | 1.080 |
Why?
| | Students | 2 | 2023 | 43 | 0.960 |
Why?
| | Gastroenteritis | 2 | 2022 | 24 | 0.960 |
Why?
| | Viruses | 2 | 2022 | 5 | 0.870 |
Why?
| | Antibodies, Neutralizing | 5 | 2021 | 31 | 0.870 |
Why?
| | Case-Control Studies | 14 | 2024 | 202 | 0.850 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 16 | 0.850 |
Why?
| | Communicable Diseases | 2 | 2022 | 9 | 0.850 |
Why?
| | Touch | 1 | 2021 | 1 | 0.850 |
Why?
| | School Health Services | 1 | 2022 | 9 | 0.840 |
Why?
| | Vaccines | 2 | 2023 | 17 | 0.840 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 19 | 0.840 |
Why?
| | Respiratory System | 1 | 2021 | 5 | 0.840 |
Why?
| | Respiratory Syncytial Virus Infections | 5 | 2023 | 41 | 0.810 |
Why?
| | Immunization Schedule | 2 | 2017 | 7 | 0.760 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 3 | 0.760 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2022 | 23 | 0.740 |
Why?
| | Asthma | 5 | 2023 | 143 | 0.700 |
Why?
| | Adult | 12 | 2024 | 1233 | 0.700 |
Why?
| | Immunoglobulins, Intravenous | 5 | 2023 | 9 | 0.690 |
Why?
| | Hematologic Diseases | 1 | 2018 | 4 | 0.680 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 8 | 0.680 |
Why?
| | Critical Care | 4 | 2021 | 12 | 0.670 |
Why?
| | Influenza A Virus, H3N2 Subtype | 6 | 2024 | 11 | 0.660 |
Why?
| | Picornaviridae Infections | 1 | 2018 | 20 | 0.650 |
Why?
| | Communicable Diseases, Emerging | 1 | 2018 | 3 | 0.650 |
Why?
| | Communicable Disease Control | 1 | 2018 | 7 | 0.640 |
Why?
| | Hyponatremia | 1 | 2017 | 2 | 0.640 |
Why?
| | Retrospective Studies | 11 | 2023 | 1251 | 0.610 |
Why?
| | Public Health Practice | 1 | 2016 | 1 | 0.590 |
Why?
| | Immunization Programs | 1 | 2016 | 6 | 0.590 |
Why?
| | Seasons | 9 | 2024 | 27 | 0.580 |
Why?
| | Infectious Disease Medicine | 2 | 2022 | 4 | 0.570 |
Why?
| | Neoplasms | 1 | 2018 | 119 | 0.570 |
Why?
| | Coronavirus Infections | 3 | 2020 | 15 | 0.540 |
Why?
| | Specialization | 1 | 2014 | 6 | 0.510 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 31 | 0.490 |
Why?
| | Treatment Outcome | 6 | 2021 | 624 | 0.490 |
Why?
| | Hospitals, Pediatric | 6 | 2022 | 178 | 0.490 |
Why?
| | Meningitis, Fungal | 1 | 2013 | 1 | 0.470 |
Why?
| | Histoplasma | 1 | 2013 | 2 | 0.470 |
Why?
| | Histoplasmosis | 1 | 2013 | 2 | 0.470 |
Why?
| | Connective Tissue Diseases | 2 | 2023 | 4 | 0.460 |
Why?
| | Pediatrics | 1 | 2014 | 170 | 0.440 |
Why?
| | Nervous System Diseases | 2 | 2023 | 13 | 0.430 |
Why?
| | Prevalence | 3 | 2023 | 145 | 0.420 |
Why?
| | Fever | 4 | 2021 | 26 | 0.410 |
Why?
| | Population Surveillance | 2 | 2021 | 12 | 0.410 |
Why?
| | Myelitis | 2 | 2022 | 5 | 0.410 |
Why?
| | Risk Factors | 4 | 2023 | 460 | 0.400 |
Why?
| | Longitudinal Studies | 3 | 2020 | 123 | 0.400 |
Why?
| | Intensive Care Units | 4 | 2023 | 17 | 0.390 |
Why?
| | Infliximab | 2 | 2021 | 7 | 0.380 |
Why?
| | Vaccines, Synthetic | 4 | 2022 | 9 | 0.380 |
Why?
| | Interferon Type I | 2 | 2022 | 5 | 0.360 |
Why?
| | Critical Illness | 3 | 2022 | 21 | 0.330 |
Why?
| | Infant, Newborn | 7 | 2022 | 790 | 0.330 |
Why?
| | Animals | 6 | 2016 | 563 | 0.320 |
Why?
| | Severity of Illness Index | 2 | 2020 | 142 | 0.310 |
Why?
| | Glucocorticoids | 3 | 2023 | 29 | 0.300 |
Why?
| | Advisory Committees | 2 | 2017 | 9 | 0.300 |
Why?
| | Cross-Over Studies | 3 | 2023 | 32 | 0.300 |
Why?
| | Length of Stay | 4 | 2020 | 227 | 0.280 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2022 | 26 | 0.270 |
Why?
| | Minority Groups | 2 | 2022 | 18 | 0.270 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 317 | 0.260 |
Why?
| | Missouri | 2 | 2023 | 78 | 0.260 |
Why?
| | Pregnancy | 5 | 2024 | 203 | 0.260 |
Why?
| | Disease Models, Animal | 2 | 2014 | 55 | 0.250 |
Why?
| | Public Health Surveillance | 2 | 2021 | 5 | 0.250 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2024 | 1 | 0.250 |
Why?
| | Vaccines, Inactivated | 1 | 2024 | 2 | 0.250 |
Why?
| | Antibody Formation | 1 | 2024 | 4 | 0.250 |
Why?
| | Transplant Recipients | 1 | 2024 | 8 | 0.240 |
Why?
| | Acute Disease | 2 | 2022 | 71 | 0.240 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2024 | 15 | 0.240 |
Why?
| | Central Nervous System Viral Diseases | 2 | 2022 | 6 | 0.240 |
Why?
| | Neuromuscular Diseases | 2 | 2022 | 7 | 0.240 |
Why?
| | Echocardiography | 3 | 2020 | 78 | 0.240 |
Why?
| | Common Data Elements | 1 | 2023 | 2 | 0.240 |
Why?
| | Acceleration | 1 | 2023 | 4 | 0.240 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 2 | 0.230 |
Why?
| | Immunoglobulin G | 2 | 2021 | 33 | 0.230 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 12 | 0.230 |
Why?
| | Disease Progression | 3 | 2023 | 104 | 0.230 |
Why?
| | Educational Status | 1 | 2023 | 20 | 0.230 |
Why?
| | Guillain-Barre Syndrome | 1 | 2023 | 1 | 0.230 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2023 | 17 | 0.230 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2022 | 14 | 0.220 |
Why?
| | Stroke | 1 | 2023 | 24 | 0.220 |
Why?
| | Enterovirus | 1 | 2023 | 12 | 0.220 |
Why?
| | Age Factors | 3 | 2021 | 203 | 0.220 |
Why?
| | Regression Analysis | 2 | 2021 | 56 | 0.220 |
Why?
| | Coinfection | 1 | 2022 | 5 | 0.220 |
Why?
| | Neutralization Tests | 3 | 2022 | 6 | 0.220 |
Why?
| | Rotavirus | 1 | 2022 | 11 | 0.220 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2022 | 1 | 0.210 |
Why?
| | Rotavirus Infections | 1 | 2022 | 15 | 0.210 |
Why?
| | Rotavirus Vaccines | 1 | 2022 | 13 | 0.210 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2020 | 64 | 0.210 |
Why?
| | Academic Medical Centers | 1 | 2022 | 9 | 0.210 |
Why?
| | Disabled Children | 1 | 2022 | 7 | 0.210 |
Why?
| | Community-Institutional Relations | 1 | 2022 | 9 | 0.210 |
Why?
| | Child, Hospitalized | 1 | 2022 | 27 | 0.210 |
Why?
| | Education, Distance | 1 | 2022 | 5 | 0.210 |
Why?
| | Urban Population | 1 | 2022 | 36 | 0.210 |
Why?
| | Herpesvirus 1, Cercopithecine | 1 | 2021 | 2 | 0.210 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2021 | 36 | 0.200 |
Why?
| | Young Adult | 5 | 2022 | 652 | 0.200 |
Why?
| | Follow-Up Studies | 2 | 2021 | 315 | 0.200 |
Why?
| | Vaccine Potency | 1 | 2021 | 7 | 0.200 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2021 | 18 | 0.200 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 116 | 0.200 |
Why?
| | Respiration, Artificial | 4 | 2023 | 16 | 0.200 |
Why?
| | Immunocompromised Host | 1 | 2020 | 7 | 0.190 |
Why?
| | Mouth | 1 | 2020 | 3 | 0.190 |
Why?
| | DNA, Viral | 1 | 2020 | 13 | 0.190 |
Why?
| | Monitoring, Physiologic | 1 | 2020 | 24 | 0.190 |
Why?
| | Postoperative Care | 1 | 2020 | 28 | 0.190 |
Why?
| | Risk Assessment | 1 | 2020 | 130 | 0.180 |
Why?
| | Prognosis | 1 | 2020 | 209 | 0.180 |
Why?
| | Biomarkers | 2 | 2021 | 120 | 0.180 |
Why?
| | Cough | 2 | 2015 | 7 | 0.170 |
Why?
| | Mothers | 3 | 2024 | 37 | 0.170 |
Why?
| | Diagnosis, Differential | 2 | 2021 | 74 | 0.170 |
Why?
| | Metabolic Diseases | 1 | 2018 | 11 | 0.170 |
Why?
| | Virus Replication | 2 | 2015 | 6 | 0.170 |
Why?
| | Recurrence | 2 | 2021 | 115 | 0.160 |
Why?
| | RNA, Messenger | 3 | 2023 | 107 | 0.160 |
Why?
| | Reassortant Viruses | 1 | 2018 | 1 | 0.160 |
Why?
| | Orthomyxoviridae | 1 | 2018 | 2 | 0.160 |
Why?
| | Organoplatinum Compounds | 1 | 2017 | 1 | 0.160 |
Why?
| | Sodium | 1 | 2017 | 7 | 0.160 |
Why?
| | Hypotension | 1 | 2017 | 4 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 3 | 2020 | 114 | 0.160 |
Why?
| | Influenza B virus | 3 | 2022 | 22 | 0.160 |
Why?
| | Patient Acuity | 3 | 2022 | 8 | 0.160 |
Why?
| | Yellow Fever Vaccine | 1 | 2017 | 1 | 0.160 |
Why?
| | Meningococcal Vaccines | 1 | 2017 | 2 | 0.150 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2017 | 3 | 0.150 |
Why?
| | Herpes Zoster Vaccine | 1 | 2017 | 2 | 0.150 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2017 | 3 | 0.150 |
Why?
| | Pneumococcal Vaccines | 1 | 2017 | 4 | 0.150 |
Why?
| | Hepatitis B Vaccines | 1 | 2017 | 2 | 0.150 |
Why?
| | Patient Discharge | 3 | 2022 | 58 | 0.150 |
Why?
| | Papillomavirus Vaccines | 1 | 2017 | 8 | 0.150 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 96 | 0.150 |
Why?
| | Mutation | 1 | 2018 | 194 | 0.150 |
Why?
| | Emergency Service, Hospital | 3 | 2024 | 129 | 0.150 |
Why?
| | Societies, Medical | 1 | 2016 | 43 | 0.140 |
Why?
| | Replicon | 1 | 2016 | 1 | 0.140 |
Why?
| | Recombination, Genetic | 1 | 2015 | 3 | 0.140 |
Why?
| | Virus Internalization | 1 | 2015 | 1 | 0.140 |
Why?
| | Jordan | 1 | 2015 | 1 | 0.140 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 4 | 0.140 |
Why?
| | Viral Vaccines | 1 | 2016 | 10 | 0.140 |
Why?
| | Tertiary Care Centers | 1 | 2015 | 10 | 0.140 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2015 | 1 | 0.140 |
Why?
| | Disease Management | 1 | 2015 | 36 | 0.130 |
Why?
| | Community Networks | 1 | 2014 | 2 | 0.130 |
Why?
| | Cross Protection | 1 | 2014 | 1 | 0.130 |
Why?
| | Seroepidemiologic Studies | 1 | 2014 | 3 | 0.130 |
Why?
| | Lung | 1 | 2015 | 65 | 0.130 |
Why?
| | Emergency Medical Services | 1 | 2014 | 14 | 0.130 |
Why?
| | Disease Transmission, Infectious | 1 | 2014 | 9 | 0.130 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 23 | 0.130 |
Why?
| | Physicians | 1 | 2014 | 22 | 0.130 |
Why?
| | Mice, Inbred DBA | 1 | 2014 | 3 | 0.130 |
Why?
| | Chemoprevention | 1 | 2014 | 4 | 0.130 |
Why?
| | Mice, Inbred BALB C | 1 | 2014 | 25 | 0.130 |
Why?
| | Genetic Variation | 1 | 2015 | 161 | 0.120 |
Why?
| | Immunotherapy | 1 | 2014 | 14 | 0.120 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 98 | 0.120 |
Why?
| | Signal Transduction | 1 | 2015 | 107 | 0.120 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2013 | 2 | 0.120 |
Why?
| | Virulence | 1 | 2013 | 7 | 0.120 |
Why?
| | Opportunistic Infections | 1 | 2013 | 7 | 0.120 |
Why?
| | Bronchiolitis | 1 | 2013 | 11 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 99 | 0.120 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 82 | 0.120 |
Why?
| | Radiography | 1 | 2013 | 38 | 0.120 |
Why?
| | Chronic Disease | 1 | 2013 | 103 | 0.110 |
Why?
| | Aftercare | 2 | 2022 | 6 | 0.110 |
Why?
| | Brain | 1 | 2013 | 74 | 0.110 |
Why?
| | Stroke Volume | 2 | 2023 | 17 | 0.110 |
Why?
| | Prisoners | 1 | 2011 | 1 | 0.110 |
Why?
| | Vietnam Conflict | 1 | 2011 | 1 | 0.110 |
Why?
| | Veterans | 1 | 2011 | 2 | 0.110 |
Why?
| | Viral Fusion Proteins | 3 | 2016 | 4 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2011 | 33 | 0.100 |
Why?
| | Obesity | 2 | 2023 | 124 | 0.100 |
Why?
| | Adaptation, Psychological | 1 | 2011 | 41 | 0.100 |
Why?
| | Inflammation | 2 | 2023 | 48 | 0.100 |
Why?
| | Immunomodulation | 2 | 2021 | 2 | 0.100 |
Why?
| | Cohort Studies | 2 | 2022 | 264 | 0.100 |
Why?
| | Sulfonylurea Compounds | 1 | 2007 | 1 | 0.080 |
Why?
| | Thiazolidinediones | 1 | 2007 | 1 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 32 | 0.070 |
Why?
| | Mice | 3 | 2015 | 290 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 38 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2015 | 26 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2015 | 76 | 0.070 |
Why?
| | Antibodies, Bacterial | 1 | 2024 | 8 | 0.060 |
Why?
| | RNA, Messenger, Stored | 1 | 2023 | 1 | 0.060 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2023 | 16 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2023 | 16 | 0.060 |
Why?
| | Crowding | 1 | 2023 | 4 | 0.060 |
Why?
| | Family Characteristics | 1 | 2023 | 10 | 0.060 |
Why?
| | Ventricular Function, Left | 1 | 2023 | 25 | 0.060 |
Why?
| | Kansas | 1 | 2023 | 49 | 0.060 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2023 | 1 | 0.060 |
Why?
| | Receptor, Notch1 | 1 | 2023 | 2 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 7 | 0.060 |
Why?
| | Research Design | 1 | 2023 | 64 | 0.060 |
Why?
| | NF-kappa B p52 Subunit | 1 | 2022 | 1 | 0.060 |
Why?
| | Haploinsufficiency | 1 | 2022 | 8 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 11 | 0.060 |
Why?
| | Autoantibodies | 1 | 2022 | 9 | 0.060 |
Why?
| | NF-kappa B | 1 | 2022 | 14 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2022 | 18 | 0.060 |
Why?
| | Adenoviridae | 1 | 2022 | 6 | 0.060 |
Why?
| | Oxygen | 1 | 2022 | 13 | 0.060 |
Why?
| | Immunity, Humoral | 1 | 2022 | 14 | 0.060 |
Why?
| | Antigens, Viral | 1 | 2022 | 7 | 0.060 |
Why?
| | Immunoassay | 1 | 2022 | 8 | 0.060 |
Why?
| | Policy | 1 | 2022 | 3 | 0.050 |
Why?
| | Viral Envelope Proteins | 1 | 2022 | 3 | 0.050 |
Why?
| | Vaccines, Attenuated | 1 | 2022 | 8 | 0.050 |
Why?
| | Inpatients | 1 | 2023 | 44 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 11 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2022 | 1 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2023 | 61 | 0.050 |
Why?
| | Pilot Projects | 1 | 2022 | 124 | 0.050 |
Why?
| | Life Support Care | 1 | 2022 | 1 | 0.050 |
Why?
| | Immunization, Secondary | 1 | 2022 | 2 | 0.050 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2022 | 28 | 0.050 |
Why?
| | Saliva | 1 | 2021 | 10 | 0.050 |
Why?
| | Specimen Handling | 1 | 2021 | 18 | 0.050 |
Why?
| | Nasopharynx | 1 | 2021 | 25 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 290 | 0.050 |
Why?
| | Propensity Score | 1 | 2021 | 8 | 0.050 |
Why?
| | Shock | 1 | 2021 | 4 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 51 | 0.050 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2021 | 10 | 0.050 |
Why?
| | Logistic Models | 1 | 2021 | 91 | 0.050 |
Why?
| | Comorbidity | 1 | 2021 | 61 | 0.050 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 9 | 0.050 |
Why?
| | Hospital Costs | 1 | 2020 | 27 | 0.050 |
Why?
| | International Classification of Diseases | 1 | 2020 | 8 | 0.050 |
Why?
| | Middle Aged | 2 | 2015 | 648 | 0.050 |
Why?
| | Time Factors | 1 | 2020 | 241 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 1999 | 1 | 0.040 |
Why?
| | Lymph Nodes | 1 | 1999 | 2 | 0.040 |
Why?
| | Cancer Vaccines | 1 | 1999 | 2 | 0.040 |
Why?
| | Melanoma | 1 | 1999 | 4 | 0.040 |
Why?
| | Drug Resistance | 1 | 2019 | 6 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2019 | 8 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 6 | 0.040 |
Why?
| | Kidney Neoplasms | 1 | 1999 | 11 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 1999 | 38 | 0.040 |
Why?
| | Materials Testing | 1 | 1998 | 1 | 0.040 |
Why?
| | Aerosols | 1 | 1998 | 4 | 0.040 |
Why?
| | Nebulizers and Vaporizers | 1 | 1998 | 8 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 1998 | 5 | 0.040 |
Why?
| | Practice Patterns, Nurses' | 1 | 2017 | 5 | 0.040 |
Why?
| | Aged | 2 | 2015 | 375 | 0.040 |
Why?
| | Algorithms | 1 | 2017 | 103 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 82 | 0.040 |
Why?
| | Alphavirus | 1 | 2016 | 1 | 0.040 |
Why?
| | Encephalitis Virus, Venezuelan Equine | 1 | 2016 | 1 | 0.040 |
Why?
| | Nose | 1 | 2016 | 4 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2016 | 12 | 0.040 |
Why?
| | Sequence Homology | 1 | 2015 | 2 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2015 | 3 | 0.030 |
Why?
| | Bronchi | 1 | 2015 | 1 | 0.030 |
Why?
| | Endosomes | 1 | 2015 | 1 | 0.030 |
Why?
| | Genome, Viral | 1 | 2015 | 4 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2015 | 3 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2015 | 6 | 0.030 |
Why?
| | Transfection | 1 | 2015 | 19 | 0.030 |
Why?
| | Phylogeny | 1 | 2015 | 21 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2015 | 19 | 0.030 |
Why?
| | Illinois | 1 | 2015 | 4 | 0.030 |
Why?
| | Dyspnea | 1 | 2015 | 4 | 0.030 |
Why?
| | Colorado | 1 | 2015 | 8 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 65 | 0.030 |
Why?
| | Respiratory Sounds | 1 | 2015 | 6 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2015 | 43 | 0.030 |
Why?
| | Cell Line | 1 | 2015 | 80 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2015 | 1 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 3 | 0.030 |
Why?
| | Viral Matrix Proteins | 1 | 2015 | 2 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2015 | 30 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2015 | 22 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2015 | 33 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2015 | 150 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 106 | 0.030 |
Why?
| | Receptors, Virus | 1 | 2015 | 2 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2015 | 2 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 24 | 0.030 |
Why?
| | Oximetry | 1 | 2015 | 9 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2015 | 54 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 94 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 38 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2011 | 4 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2011 | 36 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1990 | 1 | 0.020 |
Why?
| | Hand | 1 | 1990 | 3 | 0.020 |
Why?
| | Movement | 1 | 1990 | 6 | 0.020 |
Why?
| | Therapeutic Equivalency | 1 | 2007 | 4 | 0.020 |
Why?
| | Biological Availability | 1 | 2007 | 7 | 0.020 |
Why?
| | Drug Combinations | 1 | 2007 | 18 | 0.020 |
Why?
| | Area Under Curve | 1 | 2007 | 34 | 0.020 |
Why?
| | Sex Factors | 1 | 2007 | 71 | 0.020 |
Why?
| | Equipment Design | 1 | 1998 | 13 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1998 | 19 | 0.010 |
Why?
| | Frontal Lobe | 1 | 1990 | 1 | 0.010 |
Why?
| | Accidents, Traffic | 1 | 1990 | 14 | 0.010 |
Why?
| | Corpus Callosum | 1 | 1990 | 5 | 0.010 |
Why?
| | Craniocerebral Trauma | 1 | 1990 | 18 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|